New JP Ultraviolet-Visible and Infrared Reference Spectra Published
Recommendation
Monday, 29 September 2025 14.00 - 17.00 h
Register now for ECA's GMP Newsletter
In March 2023, the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has published the "JP Drafts (March 2023) No.2". In this context, five new Ultraviolet-visible and Infrared reference spectra were published.
The following spectra were made available as PDF files:
- Aripiprazole
- Febuxostat
- Lornoxicam
- Oxaliplatin
- Tolvaptan
New monographs of these and for a few other APIs and tablets have also been published.
The comment period runs from 01 March to 31 May 2023. To submit remarks, a form for comments has to be downloaded and sent by e-mail to the authority after it has been filled in.
Related GMP News
23.07.2025New HPTLC Chapter Proposed for The International Pharmacopoeia
22.07.2025AQCG Organises One-Day Track at PharmaLab 2025
22.07.2025ICH publishes Training Materials on Q2(R2) and Q14
22.07.2025AQCG welcomes two new Board Members
22.07.2025Free Webinar on Sampling and Sample Management: Recording & Q&A Document